title: Evaluation of the therapeutic activity of tulathromycin against swine respiratory disease on farms in Europe.
abstract: The clinical efficacy of tulathromycin in the treatment of natural outbreaks of swine respiratory disease (SRD) was evaluated at five European sites. Pigs (1 to 6 months of age) exhibiting clinical signs of SRD were treated intramuscularly with tulathromycin (n = 247) at 2.5 mg/kg on day 0 versus either tiamulin (n = 102) at 15 mg/kg on days 0, 1, and 2 (Germany, the Netherlands, and the United Kingdom) or florfenicol (n = 20) at 15 mg/kg on days 0 and 2 (France). Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae infections were the most frequently diagnosed pathogens. For both tulathromycin-treated animals and those treated with tiamulin or florfenicol, there were significant (P = .0001) reductions in mean rectal temperature and the severity of abnormal clinical signs on days 2 and 10 compared with day 0. There were no significant differences (P > .05) between treatments in average daily weight gain. Tulathromycin was found to be safe and highly effective in the treatment of natural outbreaks of SRD.
authors.affiliation: Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK.
authors.forename: Ian A
authors.initials: IA
authors.lastname: Nanjiani
authors.forename: Jo
authors.initials: J
authors.lastname: McKelvie
authors.forename: Hafid A
authors.initials: HA
authors.lastname: Benchaoui
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Godinho
authors.forename: John
authors.initials: J
authors.lastname: Sherington
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Sunderland
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Weatherley
authors.forename: Tim G
authors.initials: TG
authors.lastname: Rowan
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000662:veterinary; D004224:Diterpenes / Q000008:administration & dosage / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000662:veterinary; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012720:Severity of Illness Index; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D018942:Macrolides
chemical_list: D000900:Anti-Bacterial Agents; D004187:Disaccharides; D004224:Diterpenes; D006571:Heterocyclic Compounds; D013839:Thiamphenicol; C035534:florfenicol; C014224:tiamulin; C485204:tulathromycin; D018942:Macrolides